{"database": "lobbying", "table": "lobbying_activities", "rows": [[1558104, "6d1a8c28-a1b0-4317-9c6a-abb8f2e1155d", "Q2", "APOTEX CORP.", 310973, "APOTEX CORP.", 2014, "second_quarter", "PHA", "FDA proposed rule,Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes;Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing;\n\nProposed FDA rule, \"Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products,\" RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics;\n\nFederal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative, and;\n\nFederal policy relating to International Nonroprietary Names for Biosimilars", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", null, 160000, 0, 0, "2014-07-18T08:28:08.857000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1558104"], "units": {}, "query_ms": 32.38443803275004, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}